Review
Version 2
Preserved in Portico This version is not peer-reviewed
Synchronizing Cancer Research Worldwide, a Way of Overcoming Resistance to Anti-angiogenic Drugs
Version 1
: Received: 27 September 2022 / Approved: 29 September 2022 / Online: 29 September 2022 (08:06:17 CEST)
Version 2 : Received: 6 October 2022 / Approved: 7 October 2022 / Online: 7 October 2022 (09:45:53 CEST)
Version 2 : Received: 6 October 2022 / Approved: 7 October 2022 / Online: 7 October 2022 (09:45:53 CEST)
A peer-reviewed article of this Preprint also exists.
Swamy, K. Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model. Vaccines 2024, 12, 7. Swamy, K. Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model. Vaccines 2024, 12, 7.
Abstract
Multiple biological pathways manifest and latent, meant for human survival, become a liability in cancer cure. With an increasing understanding of innumerable complex paths, cancer progression and development of resistance is no surprise. For the three “vasculature-immune-phenotypic” fundamental changes, hypoxia is the maestro orchestrating the whole gamut of changes (through the master manipulator - HIF-1 α), simultaneously transactivating hundreds of pro-angiogenic genes. Such a complex molecular bio-network begs the question, “Is our cancer research caught in such a tangled web that we have lost sight of the Spider?”. Hypoxia is this Spider weaving compensatory webs with every intervention/ obstruction. Anti-angiogenic (AAG) research has been conducted mainly in silos – exploring independent paths. This review conceptualizes a convergence of a multitude of research worldwide to a single theme of normalizing vasculature as a primary baseline for overcoming resistance to AAGs or their combinations.
Keywords
Anti-angiogenic; HIF-1 α; Normalization-window; research; hypoxia; resistance; SBRT; Immunotherapy
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (1)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
Commenter: Kumara Swamy
Commenter's Conflict of Interests: Author